Walleye Trading’s Beam Therapeutics BEAM Stock Holding History

Walleye Trading’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-183	Closed	-$4.36K	–	3983
2026 Q1	$4.36K	Buy	+183	New	+$5.08K	﹤0.01%	3983
2025 Q3	–	Sell	-3,478	Closed	-$69.2K	–	4387
2025 Q2	$59.2K	Buy	+3,478	New	+$60.6K	﹤0.01%	3779
2023 Q3	–	Sell	-6,129	Closed	-$164K	–	4996
2023 Q2	$196K	Buy	6,129 +5,293	+633%	+$172K	﹤0.01%	3434
2023 Q1	$25.6K	Sell	836 -12,164	-94%	-$480K	﹤0.01%	4209
2022 Q4	$508K	Buy	+13,000	New	+$582K	﹤0.01%	2806
2022 Q3	–	Sell	-1,094	Closed	-$62.4K	–	5042
2022 Q2	$42K	Buy	+1,094	New	+$43.5K	﹤0.01%	4374

Other funds holding BEAM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Walleye Trading's BEAM Position: Q2 2026 in Review

Walleye Trading sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 183 shares — an estimated $4.36K sold.

Walleye Trading first reported a position in BEAM in Q2 2022 and held it in 6 quarters. The position peaked at $508K in Q4 2022. 109 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Walleye Trading reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Trading sold 183 Beam Therapeutics shares in Q2 2026, an estimated $4.36K.
Walleye Trading first reported a position in Beam Therapeutics in Q2 2022 and held it in 6 quarters.
Walleye Trading's Beam Therapeutics position peaked at $508K in Q4 2022.
109 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.